BiotechTube

Gefitinib + docetaxel + cisplatin

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-squamous Non-small Cell Lung Cancer Stage II

Conditions

Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation, NSCLC

Trial Timeline

Nov 1, 2015 → Jan 1, 2018

NCT ID
NCT02326285

About Gefitinib + docetaxel + cisplatin

Gefitinib + docetaxel + cisplatin is a phase 2/3 stage product being developed by AstraZeneca for Non-squamous Non-small Cell Lung Cancer Stage II. The current trial status is terminated. This product is registered under clinical trial identifier NCT02326285. Target conditions include Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB.

What happened to similar drugs?

3 of 20 similar drugs in Non-squamous Non-small Cell Lung Cancer Stage II were approved

Approved (3) Terminated (1) Active (16)
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄Bevacizumab + Pemetrexed + Bevacizumab + Pemetrexed + CarboplatinEli LillyPhase 3
🔄Pyrotinib + DocetaxelJiangsu Hengrui MedicinePhase 3
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
🔄Paclitaxel + Carboplatin + Cisplatin + Veliparib + PemetrexedAbbViePhase 3

Hype Score Breakdown

Clinical
15
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02326285Phase 2/3Terminated

Competing Products

20 competing products in Non-squamous Non-small Cell Lung Cancer Stage II

See all competitors
ProductCompanyStageHype Score
Bevacizumab + Pemetrexed + Bevacizumab + Pemetrexed + CarboplatinEli LillyPhase 3
40
Pyrotinib + DocetaxelJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Pemetrexed + CarboplatinJiangsu Hengrui MedicinePhase 2
31
Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
32
Paclitaxel + Carboplatin + Cisplatin + Veliparib + PemetrexedAbbViePhase 3
40
Standard of Care + Telisotuzumab Adizutecan + Osimertinib (Osi) + Cisplatin + Carboplatin + PemetrexedAbbViePhase 2/3
45
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatinAstraZenecaPhase 2
27
Rilvegostomig + Pembrolizumab + Carboplatin + Cisplatin + PemetrexedAstraZenecaPhase 3
47
Pembrolizumab + Bevacizumab + Pemetrexed + Cisplatin + Carboplatin + Dexamethasone 4 mgMerckPhase 2
39
PembrolizumabMerckPhase 2
35
pembrolizumab + lenvatinib + albumin-bound paclitaxelMerckPhase 2
42
Pembrolizumab + PemetrexedMerckPhase 2
31
Pembrolizumab + Lenvatinib + Carboplatin + PemetrexedMerckPhase 2
39
Cisplatin + Gemcitabine + Placebo + bevacizumab [Avastin] + bevacizumab [Avastin]RochePhase 3
40
ErlotinibRochePhase 2
35
erlotinib + onartuzumab + placeboRochePhase 3
40
Bevacizumab + Docetaxel + Erlotinib + PemetrexedRochePhase 3
40
Erlotinib 150 mgRochePre-clinical
26
Erlotinib + GemcitabineRochePhase 2
35
Placebo + Placebo + RG1507 + RG1507 + erlotinib [Tarceva]RochePhase 2
27